Bosh sahifa8AP • FRA
add
Agios Pharmaceuticals Inc
Yopilish kursi
25,00 €
Kunlik diapazon
25,00 € - 25,00 €
Yillik diapazon
19,70 € - 38,80 €
Bozor kapitalizatsiyasi
1,77 mlrd USD
Oʻrtacha hajm
3,00
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 19,97 mln | 86,09% |
Joriy xarajat | 51,61 mln | -0,17% |
Sof foyda | -108,04 mln | -11,93% |
Sof foyda marjasi | -541,09 | 39,85% |
Har bir ulushga tushum | -1,85 | -6,32% |
EBITDA | -120,31 mln | 2,72% |
Amaldagi soliq stavkasi | 0,93% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 854,42 mln | -4,40% |
Jami aktivlari | 1,30 mlrd | -22,00% |
Jami passivlari | 104,11 mln | -14,83% |
Umumiy kapital | 1,19 mlrd | — |
Tarqatilgan aksiyalar | 58,59 mln | — |
Narxi/balansdagi bahosi | 1,22 | — |
Aktivlardan daromad | -22,66% | — |
Kapitaldan daromad | -23,73% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -108,04 mln | -11,93% |
Operatsiyalardan naqd pul | -96,21 mln | 27,75% |
Sarmoyadan naqd pul | 90,08 mln | 283,24% |
Moliyadan naqd pul | 2,56 mln | -47,19% |
Naqd pulning sof oʻzgarishi | -3,58 mln | 97,98% |
Boʻsh pul | -62,05 mln | 42,58% |
Haqida
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Tashkil etilgan
2008
Sayt
Xodimlar soni
540
